Literature DB >> 8025584

Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies.

S Migliaresi1, U Picillo, L Ambrosone, G Di Palma, M Mallozzi, E R Tesone, G Tirri.   

Abstract

Sixty-nine unselected SLE patients were studied to evaluate the prevalence of avascular osteonecrosis (AVN) and its relationship with steroid therapy and with anticardiolipin antibodies (aCL). All the patients were under treatment with corticosteroids. AVN occurred in seven occurred in seven of the 69 patients (10.14%) and was not related to corticosteroid intake. Seventeen of the 69 patients were also treated with methylprednisolone pulse therapy (MPPT) and cumulated the highest corticosteroid doses but none of them suffered from AVN. Excluding the 17 MPPT-treated SLE patients, corticosteroid intake was significantly higher in the AVN-SLE patients. Abnormal IgG and/or IgM aCL serum levels were found in two of the seven AVN-SLE patients and in 24 of the 62 non-AVN SLE, without a statistically significant difference. None of the seven AVN-SLE patients showed features of antiphospholipid syndrome. We conclude that in SLE patients a continuous high-dose steroid treatment may be considered a risk factor for AVN. On the contrary, MPPT regimen may reduce this risk. Anticardiolipin antibodies might represent an added factor which could play a role in some patients but not in all.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025584     DOI: 10.1177/096120339400300108

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  22 in total

1.  Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?

Authors:  M Y Mok; V T Farewell; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Steroid induced osteonecrosis: An analysis of steroid dosing risk.

Authors:  Christian Powell; Christopher Chang; Stanley M Naguwa; Gurtej Cheema; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2010-07-09       Impact factor: 9.754

3.  Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study.

Authors:  Lidan Zhao; Xiuhua Wu; Honghua Wu; Jinmei Su; Wen Zhang; Yan Zhao; Xuan Zhang; Wenjie Zheng
Journal:  Rheumatol Int       Date:  2016-05-26       Impact factor: 2.631

4.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.

Authors:  J Calvo-Alén; G McGwin; S Toloza; M Fernández; J M Roseman; H M Bastian; E J Cepeda; E B González; B A Baethge; B J Fessler; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2005-11-03       Impact factor: 19.103

5.  Severe acute respiratory syndrome: clinical and laboratory manifestations.

Authors:  Christopher W K Lam; Michael H M Chan; Chun K Wong
Journal:  Clin Biochem Rev       Date:  2004-05

Review 6.  Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy.

Authors:  Waqar Haque; Huseyin Kadikoy; Omar Pacha; Joseph Maliakkal; Vu Hoang; Abdul Abdellatif
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

Review 7.  Orthopedic involvement in antiphospholipid syndrome.

Authors:  Alexander Gorshtein; Yair Levy
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

8.  Association of polymorphisms in the Interleukin 23 receptor gene with osteonecrosis of femoral head in Korean population.

Authors:  Tae-Ho Kim; Jung Min Hong; Bermseok Oh; Yoon Shin Cho; Jong-Young Lee; Hyung-Lae Kim; Jong-Eun Lee; Mi-Hyun Ha; Eui Kyun Park; Shin-Yoon Kim
Journal:  Exp Mol Med       Date:  2008-08-31       Impact factor: 8.718

9.  Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus.

Authors:  Fumio Sekiya; Ken Yamaji; Kwangseok Yang; Hiroshi Tsuda; Yoshinari Takasaki
Journal:  Rheumatol Int       Date:  2009-10-07       Impact factor: 2.631

10.  Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.

Authors:  Young Bin Joo; Yoon-Kyoung Sung; Jee-Seon Shim; Jae-Hoon Kim; Eui-Kyung Lee; Hye-Soon Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2014-10-10       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.